Oxford Biomedica Solutions
Qi Zhang is an accomplished scientist currently leading vector production at Oxford Biomedica since October 2021, focusing on AAV candidates selection, vector optimization, and pilot scale operations. Prior experience includes a role as Research Associate II at Homology Medicines, Inc., where contributions were made to gene therapy viral manufacturing processes. At DC Water, valuable collaboration took place with Columbia University and Ghent University, resulting in the development of innovative water treatment strategies and successful integration of anammox technology. Qi Zhang also gained research experience as a Research Assistant at the University of Michigan, evaluating water-rock interactions. Academic qualifications include a Master's degree in Environmental/Environmental Health Engineering from the University of Michigan and Bachelor's degrees in Engineering from Shandong University and Environmental Chemistry from Umeå University.
Oxford Biomedica Solutions
Oxford Biomedica Solutions, LLC is the high-performing, full scope Adeno-Associated Virus (AAV) vector Manufacturing and Innovation joint venture of Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), and Homology Medicines, Inc. (Nasdaq: FIXX) (“Homology”). We offer global pharmaceutical and biotechnology clients innovative manufacturing expertise in AAV and lentiviral-based cell and gene therapies. Oxford Biomedica Solutions LLC provides access to Homology’s innovative and proven end-to-end AAV manufacturing capabilities, and customers also benefit from technical synergies brought in by the Group’s know-how in lentiviral vector manufacturing. This collaborative and complementary vector-based approach has the potential to accelerate our collective mission to improve patients’ lives worldwide.